Noetik CEO and co-founder Ron Alfa, M.D., Ph.D., said the licensing of human foundation models is “a new paradigm in biotech.” With the GSK deal validating the paradigm, in Alfa’s view, Noetik ...

2026 is highlighted as the year of the singularity with Elon Musk warning of underestimated impacts; conversations with him ...

Elon Musk is very optimismi about AI + robotics leading to an age of extreme abundance. He sees a Star Trek future and not ...

The reported valuation aligns with where Manus had been headed before Meta intervened. The company had been raising new funds ...

Insilico now has a pipeline of more than 40 AI-developed drugs it is developing for conditions such as cancer, bowel and kidney disease.

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recursion Pharmaceuticals Inc has faced significant challenges in its financial performance, highlighted by a sharp decline in revenue growth, which fell to -32.98% in Q3 2025 from +30.14% in Q2 2025.

Here are the top 16 conferences to mark on your 2026 calendar for technologists, business leaders, policy experts, and those ...